JP7726791B2 - 補体活性を調節するための組成物及び方法 - Google Patents

補体活性を調節するための組成物及び方法

Info

Publication number
JP7726791B2
JP7726791B2 JP2021562971A JP2021562971A JP7726791B2 JP 7726791 B2 JP7726791 B2 JP 7726791B2 JP 2021562971 A JP2021562971 A JP 2021562971A JP 2021562971 A JP2021562971 A JP 2021562971A JP 7726791 B2 JP7726791 B2 JP 7726791B2
Authority
JP
Japan
Prior art keywords
inhibitor
zilucoplan
sustained
complement
polypeptide
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Active
Application number
JP2021562971A
Other languages
English (en)
Japanese (ja)
Other versions
JPWO2020219822A5 (https=
JP2022530042A5 (https=
JP2022530042A (ja
Inventor
ジェイ． リード、サイモン
サッカベリー、エバン
ワン、ホン
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
UCB Holdings Inc
Original Assignee
UCB Holdings Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by UCB Holdings Inc filed Critical UCB Holdings Inc
Publication of JP2022530042A publication Critical patent/JP2022530042A/ja
Publication of JPWO2020219822A5 publication Critical patent/JPWO2020219822A5/ja
Publication of JP2022530042A5 publication Critical patent/JP2022530042A5/ja
Priority to JP2025060888A priority Critical patent/JP2025118607A/ja
Application granted granted Critical
Publication of JP7726791B2 publication Critical patent/JP7726791B2/ja
Active legal-status Critical Current
Anticipated expiration legal-status Critical

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/04—Peptides having up to 20 amino acids in a fully defined sequence; Derivatives thereof
    • A61K38/12—Cyclic peptides, e.g. bacitracins; Polymyxins; Gramicidins S, C; Tyrocidins A, B or C
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/30—Macromolecular organic or inorganic compounds, e.g. inorganic polyphosphates
    • A61K47/32—Macromolecular compounds obtained by reactions only involving carbon-to-carbon unsaturated bonds, e.g. carbomers, poly(meth)acrylates, or polyvinyl pyrrolidone
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/30—Macromolecular organic or inorganic compounds, e.g. inorganic polyphosphates
    • A61K47/36—Polysaccharides; Derivatives thereof, e.g. gums, starch, alginate, dextrin, hyaluronic acid, chitosan, inulin, agar or pectin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/0019—Injectable compositions; Intramuscular, intravenous, arterial, subcutaneous administration; Compositions to be administered through the skin in an invasive manner
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/10—Dispersions; Emulsions
    • A61K9/107—Emulsions ; Emulsion preconcentrates; Micelles
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/14—Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles
    • A61K9/16—Agglomerates; Granulates; Microbeadlets ; Microspheres; Pellets; Solid products obtained by spray drying, spray freeze drying, spray congealing,(multiple) emulsion solvent evaporation or extraction
    • A61K9/1605—Excipients; Inactive ingredients
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/14—Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles
    • A61K9/16—Agglomerates; Granulates; Microbeadlets ; Microspheres; Pellets; Solid products obtained by spray drying, spray freeze drying, spray congealing,(multiple) emulsion solvent evaporation or extraction
    • A61K9/1605—Excipients; Inactive ingredients
    • A61K9/1629—Organic macromolecular compounds
    • A61K9/1641—Organic macromolecular compounds obtained otherwise than by reactions only involving carbon-to-carbon unsaturated bonds, e.g. polyethylene glycol, poloxamers
    • A61K9/1647—Polyesters, e.g. poly(lactide-co-glycolide)
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Epidemiology (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Inorganic Chemistry (AREA)
  • Immunology (AREA)
  • Dermatology (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Dispersion Chemistry (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Organic Chemistry (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Medicinal Preparation (AREA)
  • Peptides Or Proteins (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
JP2021562971A 2019-04-24 2020-04-24 補体活性を調節するための組成物及び方法 Active JP7726791B2 (ja)

Priority Applications (1)

Application Number Priority Date Filing Date Title
JP2025060888A JP2025118607A (ja) 2019-04-24 2025-04-02 補体活性を調節するための組成物及び方法

Applications Claiming Priority (7)

Application Number Priority Date Filing Date Title
US201962837978P 2019-04-24 2019-04-24
US62/837,978 2019-04-24
US201962947183P 2019-12-12 2019-12-12
US201962947188P 2019-12-12 2019-12-12
US62/947,183 2019-12-12
US62/947,188 2019-12-12
PCT/US2020/029733 WO2020219822A1 (en) 2019-04-24 2020-04-24 Compositions and methods for modulating complement activity

Related Child Applications (1)

Application Number Title Priority Date Filing Date
JP2025060888A Division JP2025118607A (ja) 2019-04-24 2025-04-02 補体活性を調節するための組成物及び方法

Publications (4)

Publication Number Publication Date
JP2022530042A JP2022530042A (ja) 2022-06-27
JPWO2020219822A5 JPWO2020219822A5 (https=) 2023-05-01
JP2022530042A5 JP2022530042A5 (https=) 2023-05-01
JP7726791B2 true JP7726791B2 (ja) 2025-08-20

Family

ID=70977557

Family Applications (2)

Application Number Title Priority Date Filing Date
JP2021562971A Active JP7726791B2 (ja) 2019-04-24 2020-04-24 補体活性を調節するための組成物及び方法
JP2025060888A Pending JP2025118607A (ja) 2019-04-24 2025-04-02 補体活性を調節するための組成物及び方法

Family Applications After (1)

Application Number Title Priority Date Filing Date
JP2025060888A Pending JP2025118607A (ja) 2019-04-24 2025-04-02 補体活性を調節するための組成物及び方法

Country Status (13)

Country Link
US (1) US20220211799A1 (https=)
EP (1) EP3958842A1 (https=)
JP (2) JP7726791B2 (https=)
KR (1) KR20220004039A (https=)
CN (1) CN113710230A (https=)
AU (1) AU2020261059A1 (https=)
BR (1) BR112021017820A2 (https=)
CA (1) CA3137895A1 (https=)
IL (1) IL287079A (https=)
MX (1) MX2021013010A (https=)
SG (1) SG11202109837SA (https=)
TW (1) TW202106290A (https=)
WO (1) WO2020219822A1 (https=)

Families Citing this family (6)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
AU2015274482B2 (en) 2014-06-12 2018-11-08 Ucb Holdings, Inc. Modulation of complement activity
EP3250230B9 (en) 2015-01-28 2022-02-23 RA Pharmaceuticals, Inc. Modulators of complement activity
ES2941640T3 (es) 2015-12-16 2023-05-24 Ra Pharmaceuticals Inc Moduladores de la actividad del complemento
MX2019006527A (es) 2016-12-07 2019-08-01 Ra Pharmaceuticals Inc Moduladores de la actividad del complemento.
KR20210080390A (ko) * 2018-10-22 2021-06-30 라 파마슈티컬스 인코포레이티드 질루코플란을 이용한 신경 질환 치료
CN113966224A (zh) 2019-06-04 2022-01-21 Ra制药公司 采用补体抑制剂的炎性疾病治疗

Citations (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP2009510048A (ja) 2005-09-27 2009-03-12 エフラット バイオポリマーズ リミテッド ゲル化疎水性注入ポリマー組成物
JP2011500753A (ja) 2007-10-27 2011-01-06 エフ．ホフマン−ラ ロシュ アーゲー 固相および溶液相の組み合わせ技法を使用するインスリン分泌性ペプチドの合成

Family Cites Families (36)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN1241139A (zh) * 1996-12-20 2000-01-12 武田药品工业株式会社 生产缓释制剂的方法
WO2000021559A2 (en) 1998-10-09 2000-04-20 Musc Foundation For Research Development Blocking factor b to treat complement-mediated immune disease
US8329169B2 (en) 2003-05-15 2012-12-11 Genentech, Inc. Methods and compositions for the prevention and treatment of sepsis
CN1289066C (zh) * 2003-09-18 2006-12-13 中国人民解放军第二军医大学 胰高血糖素样肽－1缓释微球制剂及其用途
CA2610502A1 (en) 2005-03-29 2006-10-05 Cardax Pharmaceuticals, Inc. Reduction in complement activation and inflammation during tissue injury by carotenoids, carotenoid analogs, or derivatives thereof
CA2610340C (en) 2005-05-26 2016-02-16 Vernon Michael Holers Inhibition of the alternative complement pathway for treatment of traumatic brain injury, spinal cord injury and related conditions
EP3299027A1 (en) 2005-11-04 2018-03-28 Genentech, Inc. Use of complement pathway inhibitors to treat ocular diseases
CN101341254A (zh) * 2005-12-24 2009-01-07 蒂加斯克乳制品研究中心 反-10，顺-12十八碳二烯酸的生产方法
US20090028832A1 (en) * 2006-08-10 2009-01-29 Chung Leland F Compositions and methods for targeted tumor therapy
LT3028716T (lt) 2006-10-10 2020-12-10 Regenesance B.V. Komplemento slopinimas nervų regeneracijos pagerinimui
US7736860B2 (en) 2006-11-09 2010-06-15 Univeristy Of Massachusetts Methods of identifying compounds for the treatment of sterile inflammation
US20100015139A1 (en) 2008-07-10 2010-01-21 Rekha Bansal METHOD OF INHIBITING COMPLEMENT ACTIVATION WITH FACTOR Ba SPECIFIC ANTIBODIES AND USE THEREOF
US20080269318A1 (en) 2007-04-30 2008-10-30 Carmelo Romano Treatment of age-related macular degeneration using inhibitors of complement factor d
BRPI0812767A2 (pt) 2007-06-07 2014-12-02 Genentech Inc Anticorpos para c3b e métodos para prevenção e tratamento de distúrbios associados ao complemento
WO2009014633A1 (en) 2007-07-20 2009-01-29 Trustees Of The University Of Pennsylvania Method of treating acute respiratory distress syndrome
WO2010025510A1 (en) 2008-09-03 2010-03-11 Xenome Ltd Libraries of peptide conjugates and methods for making them
US20100086596A1 (en) * 2008-10-06 2010-04-08 Oakwood Laboratories LLC Microspheres for releasing an octreotide compound without an initial time lag
LT2894165T (lt) 2008-11-10 2023-03-10 Alexion Pharmaceuticals, Inc. Būdai ir kompozicijos, skirti su komplementu susijusių sutrikimų gydymui
CN102781471B (zh) 2009-10-16 2016-10-12 奥默罗斯公司 通过抑制masp-2依赖性补体活化治疗弥散性血管内凝血的方法
WO2011106635A1 (en) 2010-02-25 2011-09-01 The Trustees Of The University Of Pennsylvania Treatment of sepsis using complement inhibitors
EP2563359A1 (en) 2010-04-30 2013-03-06 Allergan, Inc. Novel treatment for age related macular degeneration and ocular ischemic disease associated with complement activation by targeting 5-lipoxygenase
TW201241008A (en) * 2010-10-01 2012-10-16 Alexion Pharma Inc Polypeptides that bind to human complement component C5
KR101870915B1 (ko) 2011-04-08 2018-06-25 유니버시티 오브 레스터 Ｍａｓｐ-2 의존적 보체 활성화와 관련된 질병을 치료하는 방법
WO2012162215A1 (en) 2011-05-20 2012-11-29 The Trustees Of The University Of Pennsylvania Promotion of fracture healing using complement inhibitors
WO2012174055A1 (en) 2011-06-13 2012-12-20 The Trustees Of The University Of Pennsylvania Wound healing using complement inhibitors
US20130246083A1 (en) 2012-03-16 2013-09-19 Alexion Pharmaceuticals, Inc. Methods of distributing complement-inhibiting drugs to patients receiving a complement inhibitor
US9579360B2 (en) 2012-06-20 2017-02-28 The Trustees Of The University Of Pennsylvania Methods of treating or preventing periodontitis and diseases associated with periodontitis
US20130345257A1 (en) 2012-06-26 2013-12-26 The Regents Of The University Of California Composition for lupus nephritis and methods of making and using the same
WO2014078622A1 (en) 2012-11-15 2014-05-22 The Brigham And Women's Hospital, Inc. Method and system for diagnosing and treating preeclampsia
US20140234275A1 (en) 2013-02-15 2014-08-21 Jason Williams Method for treating als via the increased production of factor h
US20160324798A1 (en) * 2013-12-31 2016-11-10 Heron Therapeutics, Inc. Polymer-based compositions for extended release of proteins
AU2015274482B2 (en) * 2014-06-12 2018-11-08 Ucb Holdings, Inc. Modulation of complement activity
WO2016138520A1 (en) 2015-02-27 2016-09-01 The Johns Hopkins University Assay to diagnose and treat disorders of the alternative pathway of complement activation
ES2941640T3 (es) 2015-12-16 2023-05-24 Ra Pharmaceuticals Inc Moduladores de la actividad del complemento
MX2019006527A (es) 2016-12-07 2019-08-01 Ra Pharmaceuticals Inc Moduladores de la actividad del complemento.
TWI826364B (zh) * 2017-04-03 2023-12-21 德商因夫萊亞斯有限公司 活性抑制劑於發炎性疾病之治療

Patent Citations (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP2009510048A (ja) 2005-09-27 2009-03-12 エフラット バイオポリマーズ リミテッド ゲル化疎水性注入ポリマー組成物
JP2011500753A (ja) 2007-10-27 2011-01-06 エフ．ホフマン−ラ ロシュ アーゲー 固相および溶液相の組み合わせ技法を使用するインスリン分泌性ペプチドの合成

Non-Patent Citations (5)

* Cited by examiner, † Cited by third party
Title
Beecher, G. et al.，Therapies Directed Against B-Cells and Downstream Effectors in Generalized Autoimmune Myasthenia Gravis: Current Status，Drugs，2019年02月14日，Vol.79, No.4，p.353-364，doi:10.1007/s40265-019-1065-0
Lee, P. W., & Pokorski, J. K.，Poly(lactic-co-glycolic acid) devices: Production and applications for sustained protein delivery，Wiley Interdisciplinary Reviews. Nanomedicine and Nanobiotechnology，2018年，Vol.10, No.5，e1516，doi:10.1002/wnan.1516
Mastellos, D. C. et al.，Expanding Complement Therapeutics for the Treatment of Paroxysmal Nocturnal Hemoglobinuria，Seminars in Hematology，2018年，Vol.55, No.3，p.167-175，doi:10.1053/j.seminhematol.2018.02.002
岡田 弘晃，生分解性長期徐放性注射剤，薬剤学: 生命とくすり，2008年，第68巻，第2号，p.136-142
西尾 玲士 ほか，ポリマーナノ粒子集合体を用いたバイオ医薬DDS技術の開発，薬剤学: 生命とくすり，2010年，第70巻，第1号，p.14-20

Also Published As

Publication number Publication date
CN113710230A (zh) 2021-11-26
KR20220004039A (ko) 2022-01-11
EP3958842A1 (en) 2022-03-02
JP2025118607A (ja) 2025-08-13
CA3137895A1 (en) 2020-10-29
BR112021017820A2 (pt) 2022-02-08
MX2021013010A (es) 2022-01-18
AU2020261059A1 (en) 2021-10-14
WO2020219822A1 (en) 2020-10-29
SG11202109837SA (en) 2021-10-28
IL287079A (en) 2021-12-01
TW202106290A (zh) 2021-02-16
US20220211799A1 (en) 2022-07-07
JP2022530042A (ja) 2022-06-27

Similar Documents

Publication Publication Date Title
JP7726791B2 (ja) 補体活性を調節するための組成物及び方法
JP7379615B2 (ja) 補体活性のモジュレーター
US20220160820A1 (en) Modulators of complement activity
JP2021505565A (ja) 補体活性のモジュレータ
HK40084222A (en) Modulators of complement activity
HK40084222B (zh) 补体活性的调节剂
HK40031446B (en) Modulators of complement activity
HK40031446A (en) Modulators of complement activity

Legal Events

Date Code Title Description
A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20230421

A621 Written request for application examination

Free format text: JAPANESE INTERMEDIATE CODE: A621

Effective date: 20230421

A977 Report on retrieval

Free format text: JAPANESE INTERMEDIATE CODE: A971007

Effective date: 20240327

A131 Notification of reasons for refusal

Free format text: JAPANESE INTERMEDIATE CODE: A131

Effective date: 20240507

A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20240802

A02 Decision of refusal

Free format text: JAPANESE INTERMEDIATE CODE: A02

Effective date: 20241203

A711 Notification of change in applicant

Free format text: JAPANESE INTERMEDIATE CODE: A712

Effective date: 20250225

A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20250402

TRDD Decision of grant or rejection written
A01 Written decision to grant a patent or to grant a registration (utility model)

Free format text: JAPANESE INTERMEDIATE CODE: A01

Effective date: 20250722

A61 First payment of annual fees (during grant procedure)

Free format text: JAPANESE INTERMEDIATE CODE: A61

Effective date: 20250807

R150 Certificate of patent or registration of utility model

Ref document number: 7726791

Country of ref document: JP

Free format text: JAPANESE INTERMEDIATE CODE: R150